Celadon Pharmaceuticals PLC Change of Name (3693G)
March 29 2022 - 3:00AM
UK Regulatory
TIDMCEL
RNS Number : 3693G
Celadon Pharmaceuticals PLC
29 March 2022
29 March 2022
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Change of name
Further to yesterday's announcement, the Company confirms that,
the change of name from Summerway Capital plc to Celadon
Pharmaceuticals Plc, is effective on the London Stock Exchange as
of today.
As a result, the Company's stock market ticker is now CEL and
its ISIN and SEDOL remain unchanged. The change of name will not
affect any rights of shareholders and existing share certificates
should be retained as they will remain valid and no new share
certificates will be issued.
Enquiries:
Celadon Pharmaceuticals Plc
Mo Noonan 078 764 44977
Canaccord Genuity Limited (Nominated Adviser
and Broker)
Andrew Potts / Patrick Dolaghan 020 7523 800
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company
targeting the research, cultivation, manufacturing and supply of
cannabinoid-based medicines. Its primary focus is on improving
quality of life for chronic pain sufferers, as well as exploring
the potential of cannabinoid-based medicines for other conditions
such as autism. Its UK facility comprises a laboratory designed to
meet UK-GMP standards, and capacity for a large indoor hydroponic
growing facility that has received a Home Office Licence to legally
grow high THC medicinal cannabis for the purpose of producing test
batches of cannabis oil to support its application to the MHRA. The
Company's subsidiary, LVL, owns a MHRA conditionally approved
cannabis trial using cannabis based medicinal products to treat
chronic pain in the UK.
For further information please visit our website
www.celadonpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CANSEMSMUEESEID
(END) Dow Jones Newswires
March 29, 2022 03:00 ET (07:00 GMT)
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jul 2023 to Jul 2024